References
- Qiu L, Zheng H, Zhao X. The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis. BMC Cancer 2019; 19: 273. doi: 10.1186/s12885-019-5466-y
- Minghan Q, Shan W, Xinrui C, Huaqing W. Update on diffuse large B-cell lymphoma: highlights from the 2022 ASCO Annual Meeting. Cancer Biol Med 2022; 19: 1117–20. doi: 10.20892/j.issn.2095-3941.2022.0403
- Wang C, Shi F, Liu Y, Zhang Y, Dong L, Li X, et al. Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy. J Hematol Oncol 2021; 14: 106. doi: 10.1186/s13045-021-01120-3
- Lu T, Zhang J, Xu-Monette ZY, Young KH. The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma. Exp Hematol Oncol 2023; 12: 72. doi: 10.1186/s40164-023-00432-z
- Guan J, Zhang J, Zhang X, Yuan Z, Cheng J, Chen B. Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating non-Hodgkin lymphoma: A systematic review and meta-analysis of clinical trials. Medicine 2022; 101: e32333. doi: 10.1097/MD.0000000000032333
- Xie M, Huang X, Ye X, Qian W. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma. Int Immunopharmacol 2019; 77: 105999. doi: 10.1016/j.intimp.2019.105999
- Boydell E, Sandoval JL, Michielin O, Obeid M, Addeo A, Friedlaender A. Neoadjuvant immunotherapy: A promising new standard of care. Int J Mol Sci 2023; 24: 11849. doi: 10.3390/ijms241411849
- Hu LY, Xu XL, Rao HL, Chen J, Lai RC, Huang HQ, et al. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study. Chin J Cancer 2017; 36: 94. doi: 10.1186/s40880-017-0262-z
- Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol 2017; 14: 203–20. doi: 10.1038/nrclinonc.2016.168
- Jelinek T, Mihalyova J, Kascak M, Duras J, Hajek R. PD-1/PD-L1 inhibitors in haematological malignancies: update 2017. Immunology 2017;152: 357–71. doi: 10.1111/imm.12788
- Ok CY, Young KH. Checkpoint inhibitors in hematological malignancies. J Hematol Oncol 2017; 10: 103. doi: 10.1186/s13045-017-0474-3
- Wang Y, Wu L, Tian C, Zhang Y. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas. Ann Hematol 2018; 97: 229–37. doi: 10.1007/s00277-017-3176-6
- Annibali O, Crescenzi A, Tomarchio V, Pagano A, Bianchi A, Grifoni A, et al. PD-1 /PD-L1 checkpoint in hematological malignancies. Leuk Res 2018; 67: 45–55. doi: 10.1016/j.leukres.2018.01.014
- Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D, et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 2015; 126: 2193–201. doi: 10.1182/blood-2015-02-629600
- Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, WHO classification of tumours, Revised 4th edition, Volume 2. France: International Agency for Research on Cancer; 2017.
- Fang X, Xiu B, Yang Z, Qiu W, Zhang L, Zhang S, et al. The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma. Medicine 2017; 96: e6398. doi: 10.1097/MD.0000000000006398
- Kwon D, Kim S, Kim PJ, Go H, Nam SJ, Paik JH, et al. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. Histopathology 2016; 68: 1079–89. doi: 10.1111/his.12882
- Gravelle P, Burroni B, Péricart S, Rossi C, Bezombes C, Tosolini M, et al. Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies. Oncotarget 2017; 8: 44960–75. doi: 10.18632/oncotarget.16680
- Zeng Q, Liu Z, Liu T. Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysis. BMC Cancer 2020; 20: 59. doi: 10.1186/s12885-020-6550-z
- Xie W, Medeiros LJ, Li S, Yin CC, Khoury JD, Xu J. PD-1/PD-L1 pathway and Its blockade in patients with classic Hodgkin lymphoma and Non-Hodgkin large-cell lymphomas. Curr Hematol Malig Rep 2020; 15: 372–81. doi: 10.1007/s11899-020-00589-y
- Xing W, Dresser K, Zhang R, Evens AM, Yu H, Woda BA, Chen BJ. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. Oncotarget 2016; 7: 59976–86. doi: 10.18632/oncotarget.11045
- Shiozawa E, Yamochi-Onizuka T, Takimoto M, Ota H: The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries. Leuk Res 2007; 31: 1579–83. doi: 10.1016/j.leukres.2007.03.017
- Muenst S, Hoeller S, Willi N, Dirnhofera S, Tzankov A. Diagnostic and prognostic utility of PD-1 in B cell lymphomas. Dis Markers 2010; 29: 47–53. doi: 10.3233/DMA-2010-0725
- Laurent C, Charmpi K, Gravelle P, Tosolini M, Franchet C, Ysebaert L, et al. Several immune escape patterns in non-Hodgkin’s lymphomas. Oncoimmunology 2015; 4: e1026530. doi: 10.1080/2162402X.2015.1026530
- Karakatsanis S, S Papadatos S, Syrigos N, Marinos L, Pouliou E, Papanikolaou A. Clinical significance of PD-1 and PD-L1 molecules in patients with diffuse large B-cell lymphoma, not otherwise specified: Correlation with clinical and pathological findings. J BUON 2021; 26: 569–79.
- Desouki MM, Post GR, Cherry D, Lazarchick J. PAX-5: a valuable immunohistochemical marker in the differential diagnosis of lymphoid neoplasms. Clin Med Res 2010; 8: 84–8. doi: 10.3121/cmr.2010.891
- Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–82. doi: 10.1182/blood-2003-05-1545
- Boltezar L, Kloboves-Prevodnik V, Pohar-Perme M, Gasljevic G, Jezersek-Novakovic B. Comparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma. Oncol Lett 2018; 15: 6903–12. doi: 10.3892/ol.2018.8243
- Chen BJ, Dashnamoorthy R, Galera P, Makarenko V, Chang H, Ghosh S, et al. The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma. Oncotarget 2019; 10: 2030–40. doi: 10.18632/oncotarget.26771
- Xu-Monette ZY, Xiao M, Au Q, Padmanabhan R, Xu B, Hoe N, et al. Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL. Cancer Immunol Res 2019; 7: 644–57. doi: 10.1158/2326-6066.CIR-18-0439
- International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993; 329: 987–94. doi: 10.1056/NEJM199309303291402
- McCord R, Bolen CR, Koeppen H, Kadel EE 3rd, Oestergaard MZ, Nielsen T, et al. PD-L1 and tumor-associated macrophages in de novo DLBCL. Blood Adv 2019; 3: 531–40. doi: 10.1182/bloodadvances.2018020602
- Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013; 19: 3462–73. doi: 10.1158/1078-0432.CCR-13-0855
- Zhang T, Xie J, Arai S, Wang L, Shi X, Shi N, et al. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget 2016; 7: 73068–79. doi: 10.18632/oncotarget.12230
- Kwon HJ, Yang JM, Lee JO, Lee JS, Paik JH. Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma. J Transl Med 2018; 16: 320. doi: 10.1186/s12967-018-1689-y